ENTYVIO (VEDOLIZUMAB) 300MG
ENTYVIO (VEDOLIZUMAB) 300MG, Entyvio 300mg 20ml Injection Single Dose Vial
Entyvio® is a recombinant humanized anti-α4β7-integrin monoclonal antibody; an immunomodulatory agent that selectively inhibits lymphocyte recruitment to the GI tract.
Entyvio is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker, immunomodulator or demonstrated dependence on corticosteroids.
ENTYVIO (VEDOLIZUMAB) 300MG, Entyvio 300mg 20ml Injection Single Dose Vial
Entyvio® is a recombinant humanized anti-α4β7-integrin monoclonal antibody; an immunomodulatory agent that selectively inhibits lymphocyte recruitment to the GI tract.
Entyvio is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker, immunomodulator or demonstrated dependence on corticosteroids.
ENTYVIO (VEDOLIZUMAB) 300MG, Entyvio 300mg 20ml Injection Single Dose Vial
Entyvio® is a recombinant humanized anti-α4β7-integrin monoclonal antibody; an immunomodulatory agent that selectively inhibits lymphocyte recruitment to the GI tract.
Entyvio is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker, immunomodulator or demonstrated dependence on corticosteroids.
ENTYVIO (VEDOLIZUMAB) 300MG, Entyvio 300mg 20ml Injection Single Dose Vial
Entyvio® is a recombinant humanized anti-α4β7-integrin monoclonal antibody; an immunomodulatory agent that selectively inhibits lymphocyte recruitment to the GI tract.
Entyvio is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker, immunomodulator or demonstrated dependence on corticosteroids.